Back to all studies
RecruitingNCT05850689

Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

This study is recruiting. It focuses on depression and currently lists participation information in Bulgaria, France, India, Lithuania, Serbia, Spain, and the United States.

DepressionDrugFrom 18 Years to 65 Years
In plain English

Key information made simple

This study is comparing Lumateperone with placebo for people with depression. Participants receive Lumateperone or placebo and complete study visits and assessments. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.

What to expect

Your next step

The official record suggests in-person participation through a clinic, with sites including Clinical Site in Huntsville, Clinical Site in Pico Rivera, and Clinical Site in Farmington. Participation appears to involve guided sessions or support activities with check-ins on how they fit into daily life. The main fit is usually matching the main diagnosis, while common reasons not to take part include active substance or alcohol problems that could affect the results and safety concerns that need urgent care first. This is a later-stage study, which usually means a larger group and a closer look at how well the approach holds up.

Public study data

Key study information

Condition
Major Depressive Disorder
Study status
Recruiting
Sponsor / lead affiliation
Intra-Cellular Therapies, Inc.
Location / country
Bulgaria, France, India, Lithuania, Serbia, Spain, United States
Registry
ClinicalTrials.gov
Why this study may matter

Why this study may matter

This study may matter because it adds public evidence around depression. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.

Before joining

Questions to ask before joining

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Open source record
Need help deciding?

Ask HopeStage to review this study with me

This form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.

Loading the security check...
Study reference: NCT05850689. We only ask for your email here. HopeStage can help you review the study, but this is not a medical eligibility decision.
In practice

For you

Taking part may give access to a new approach being evaluated.

It requires regular visits and structured follow-up.

Requires travel, with in-person participation in Bulgaria.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

Study clarity

Things to check before joining

Sponsor
Intra-Cellular Therapies, Inc.
Sponsor type
Other organization
Main activity
medication or study treatment
Intervention
Not available
Time commitment
multiple visits or assessments
Study phase
Not available
Enrollment
Not available
Recruitment status
Recruiting
Source
Official registry link
FAQ

Questions about this study

What is Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder?

This study is exploring medication or study treatment for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. It includes a comparison with placebo. Direct benefit is not guaranteed.

Who is behind this study, and what type of sponsor is it?

This study is sponsored by Intra-Cellular Therapies, Inc.. Based on the sponsor name or official registry information, it appears to be another type of organization. You should verify the details in the official registry record.

What does participation involve, what phase is it, and what should I ask about safety?

This study may involve medication or study treatment, study visits, and assessments. The time commitment is multiple visits or assessments. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.

Where can I verify the study details?

Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.

Study of Lumateperone as Adjunctive Therapy in the. — Depression Clinical Trial | HopeStage